Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 329

1.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
2.
3.

A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.

Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ.

J Womens Health (Larchmt). 2015 Apr;24(4):281-90. doi: 10.1089/jwh.2014.4900.

PMID:
25860107
4.

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.

J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu.

PMID:
20797382
5.
6.
7.

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan P, Kane CP, Cohen LS.

Menopause. 2010 Jul;17(4):700-11. doi: 10.1097/gme.0b013e3181d88962.

PMID:
20539246
8.
9.

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Clayton AH, Kornstein SG, Dunlop BW, Focht K, Musgnung J, Ramey T, Bao W, Ninan PT.

J Clin Psychiatry. 2013 Oct;74(10):1010-7. doi: 10.4088/JCP.12m08065.

PMID:
24229754
10.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.

Int Clin Psychopharmacol. 2007 Nov;22(6):338-47.

PMID:
17917552
11.

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.

Liebowitz MR, Tourian KA, Hwang E, Mele L; Study 3362 Investigators.

BMC Psychiatry. 2013 Mar 22;13:94. doi: 10.1186/1471-244X-13-94.

12.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
13.

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.

Maity N, Ghosal MK, Gupta A, Sil A, Chakraborty S, Chatterjee S.

Indian J Pharmacol. 2014 Jul-Aug;46(4):433-7. doi: 10.4103/0253-7613.135959.

14.
15.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.

Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.

PMID:
24096053
16.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
17.

Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.

Iwata N, Tourian KA, Hwang E, Mele L, Vialet C.

J Psychiatr Pract. 2013 Jan;19(1):5-14. doi: 10.1097/01.pra.0000426323.59698.64.

PMID:
23334675
18.

Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.

Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ.

J Clin Psychopharmacol. 2011 Oct;31(5):569-76. doi: 10.1097/JCP.0b013e31822c0a68.

PMID:
21869698
19.

Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.

Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA.

J Clin Psychiatry. 2013 Feb;74(2):158-66. doi: 10.4088/JCP.12m07974.

PMID:
23473348
20.

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA.

Curr Med Res Opin. 2008 Jul;24(7):1877-90. doi: 10.1185/03007990802161923 . Epub 2008 May 27.

PMID:
18507895

Supplemental Content

Support Center